ReviewWorld journal of clinical oncology2015
Colon cancer and the epidermal growth factor receptor: Current treatment paradigms, the importance of diet, and the role of chemoprevention.
Review in World journal of clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 129 citations in OpenAlex.
- Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial.PloS one · 2018Trial
- Proteomic Analysis of Primary Colon Cancer and Synchronous Solitary Liver Metastasis.Cancer genomics & proteomicsTrial
- Amphiregulin drives EGFR-dependent genome stability in colorectal cancer and represents a targetable vulnerability.Oncogene · 2026Article
- Decoding the Apical-Basal Surfaceome of Colon Epithelial Cells via Side-Selective Biotinylation.Biomolecules · 2026Article
- Orthogonal Tri-Modular Coiled-Coil Assembly for Programmable Multi-Cargo Display on Escherichia coli Nissle 1917.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Lysosome-dependent cell death reveals a prognostic signature in colorectal cancer via integrated analysis of scRNA-seq and bulk RNA-seq data.Translational cancer research · 2026Article
- Emerging Molecular Insights and Targeted Therapeutics in Colorectal Cancer: From Emerging Approaches to Personalized Medicine.Journal of gastrointestinal cancer · 2026Review
- Metastatic colorectal adenocarcinoma with APC and EGFR L858R co-mutations: a case report.The oncologist · 2026Article
- Integrin αvβ3 is a Potential Therapeutic Target in Cholangiocarcinoma.International journal of medical sciences · 2026Article
- Impact of neoadjuvant cetuximab on liver function and tumor reduction in a murine model of selective portal vein ligation.Clinical & experimental metastasis · 2025Article
- Discovery of novel natural product-derived EGFR inhibitors using multiple linear regression, stacked ensemble regression, and fingerprinting approaches.Journal of computer-aided molecular design · 2025Article
- Epidermal growth factor receptor-targeted near-infrared probe cetuximab-IRDye800CW enables stable and tumor-specific fluorescence imaging in colorectal cancer models.Journal of biomedical optics · 2025Article
- Unlocking the Therapeutic Potential of Cyclic Peptide-Based Nanocarriers for Enhanced Colon Cancer Treatment.The protein journal · 2025Review
- Contrasting Impacts of Targeted Disruption of the Cancer Stem Cell Marker CD133 and Its Epigenetic Regulator TRIM28 in Colorectal Cancer Cells.International journal of molecular sciences · 2025Article
- p53 in colorectal cancer: from a master player to a privileged therapy target.Journal of translational medicine · 2025Review
- Shared neoantigens for cancer immunotherapy.Molecular therapy. Oncology · 2025Review
- Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).International journal of oncology · 2025Review
- Elucidation of Factors Affecting the Age-Dependent Cancer Occurrence Rates.International journal of molecular sciences · 2024Article
- USP21-EGFR signaling axis is functionally implicated in metastatic colorectal cancer.Cell death discovery · 2024Article
- Redefining Therapeutic Approaches in Colorectal Cancer: Targeting Molecular Pathways and Overcoming Resistance.International journal of molecular sciences · 2024Review
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Colorectal cancer represents the third most common and the second deadliest type of cancer for both men and women in the United States claiming over 50000 lives in 2014. The 5-year survival rate for patients diagnosed with metastatic colon and rectal cancer is < 15%. Early detection and more effective treatments are urgently needed to reduce morbidity and mortality of patients afflicted with this disease. Here we will review the risk factors and current treatment paradigms for colorectal cancer, with an emphasis on the role of chemoprevention as they relate to epidermal growth factor receptor (EGFR) blockade. We will discuss how various EGFR ligands are upregulated in the presence of Western diets high in saturated and N-6 polyunsaturated fats. We will also outline the various mechanisms of EGFR inhibition that are induced by naturally occurring chemopreventative agents such as ginseng, green tea, and curcumin. Finally, we will discuss the current role of targeted chemotherapy in colon cancer and outline the limitations of our current treatment options, describing mechanisms of resistance and escape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.